Powered by Forefront Collaborative, ImmerseRx mNSCLC Immunotherapy is an interactive learning tool that explores tumor immune evasion pathways in metastatic non-small cell lung cancer (mNSCLC), such as the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, and how immunotherapy targets these pathways to lead to tumor cell death. Moving through four interactive scenes, users will also learn about biomarker testing that is necessary to inform treatment decisions around immunotherapy for mNSCLC.
Pinch in and zoom out to scale, rotate, raise, or lower the models; and walk around the 3D objects to view animations up close. This app was created for medical oncologists, oncology nurse practitioners and physician assistants, pulmonologists, pathologists, and other healthcare professionals who are involved in the care of patients with mNSCLC.
This app is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Note: after the creation of this app, additional immunotherapy combinations were approved as first-line treatment options for mNSCLC: cemiplimab plus platinum-based chemotherapy and tremelimumab plus durvalumab plus platinum-based chemotherapy.